India says gap between vaccine doses based on scientific evidence



NEW DELHI, June 16 (Reuters) - India's government on Wednesday defended its decision to double the gap between the two doses of the AstraZeneca AZN.L COVID-19 vaccine to up to 16 weeks, after three scientific advisers said there was no agreement on such a wide interval.

Reuters reported on Tuesday that the government increased the gap last month without the approval of the scientific group that it said recommended the move, citing three members of the National Technical Advisory Group on Immunisation (NTAGI) advisory body.

In multiple statements on Wednesday, the government said the interval was increased based on scientific evidence after thorough discussions among members of NTAGI as well as its working group on COVID-19 in two meetings held in May.

The AstraZeneca shot, made locally and branded Covishield, accounts for nearly 90% of the 259 million doses administered in India, where some states have curtailed vaccination programmes over supply constraints.

The government said a NTAGI working group on May 10 initially recommended increasing the dosing interval to 12-16 weeks, a proposal that was subsequently taken up by a larger NTAGI committee on May 13.

The committee advised that "as per the COVID-19 working group recommendation, a dosing interval of a minimum three months between two doses of Covishield vaccine was recommended", the government said in a statement.

According to the minutes Link ' of an NTAGI meeting held on May 28, the interval was increased based on real-world data from Britain that showed 65% to 88% protection after the first dose, if the gap was up to 12 weeks.

"Therefore, based on the real-world evidence, dose intervals between two doses of Covishield was increased from 4-8 weeks to 12-16 weeks," said the minutes published on the health ministry's website Link

J.P. Muliyil, a member of the COVID working group, had told Reuters on Tuesday there had been discussions within the NTAGI on increasing the vaccine dosage interval but that the body had not specifically recommended 12-16 weeks.

NTAGI members had told Reuters that the group had no data concerning the effects of a gap beyond 12 weeks.

N.K. Arora, chairman of the NTAGI working group, said in a statement that the decision to expand the gap to up to 16 weeks had been made to provide "flexibility" for those who may not be able to get the second dose at 12 weeks.
Reporting by Devjyot Ghoshal and Krishna N. Das; Editing by Sanjeev Miglani, Raju Gopalakrishnan and Mark Heinrich

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Gumagamit kami ng cookies para mabigyan ka ng mahusay na karanasan sa aming website. Magbasa pa o palitan ang iyong cookie settings.

Babala sa Risk: Ang iyong kapital ay maaaring malugi. Ang mga produktong naka-leverage ay maaaring hindi para sa lahat. Tingnan ang aming Risk Disclosure.